Contract Manufacturing for Medical Devices: A Buyer’s Guide for Biologic and Combination Products

Introduction: When One Checklist Is Never Enough

The medical device contract manufacturing market is on a steep growth trajectory, projected to expand from USD 83.77 billion in 2025 to USD 140.84 billion by 2030 at a compound annual growth rate of 10.9% (MarketsandMarkets). Yet despite this expansion, most buyer guidance still treats contract manufacturing organization (CMO) selection as a single-framework exercise: verify ISO 13485, confirm cleanroom classification, check scalability, sign the contract. For a conventional Class II device, that approach may suffice. For advanced products, it is dangerously incomplete.

This is the dual-framework problem. Biologic-device combination products, advanced therapy medicinal products (ATMPs), and regenerative medicine constructs simultaneously trigger FDA device quality management system requirements, pharmaceutical current good manufacturing practice (cGMP) obligations, and, in some cases, European Medicines Agency (EMA) ATMP GMP frameworks. A partner qualified for one may be entirely unequipped for the others.

The timing of this challenge is significant. The FDA’s Quality Management System Regulation (QMSR) took effect on February 2, 2026, harmonizing U.S. device quality requirements with ISO 13485:2016. While the QMSR streamlined one dimension of compliance, it did not simplify the layered burden facing combination product manufacturers. In several respects, it raised the stakes.

This guide is built for the B2B decision-makers navigating that complexity: procurement managers, biotech founders, and healthcare executives evaluating outsourcing partners for convergence-zone products. It covers the regulatory architecture, the real implications of the QMSR, ATMP-specific manufacturing realities, intellectual property (IP) risk, and a practical framework for vetting partners who operate at the intersection of these disciplines.

The Market Landscape: Why Advanced Product Outsourcing Is Accelerating

Outsourcing is no longer a fallback for companies short on capacity. It has become a deliberate strategic posture. Nearly 87% of biopharmaceutical companies now outsource at least part of their development or manufacturing activities, reflecting a structural shift toward strategic partnership rather than purely capacity-driven decisions.

The capital economics explain much of this. Building a new biologics manufacturing facility costs between USD 200 million and USD 500 million and takes five or more years to complete. Outsourcing reduces capital expenditure by 40% to 60%, making contract development and manufacturing organizations (CDMOs) essential for most emerging biotech companies that cannot afford to divert scarce capital into infrastructure.

The fastest-growing sub-segment tells the sharpest story. The ATMP CDMO market, covering cell, gene, and tissue-engineered products, was valued at USD 7.75 billion in 2025 and is projected to reach USD 54.89 billion by 2035 at a 21.65% CAGR (SNS Insider). That is the highest growth rate in the entire contract manufacturing space.

Underlying much of this is pharma-medtech convergence, identified in Alira Health’s 2026 annual report as the defining growth accelerator of the current cycle. The drug delivery systems segment alone was valued at USD 15.2 billion in 2025. As biologics increasingly rely on sophisticated delivery mechanisms, the boundary between drug and device continues to dissolve.

The fastest-growing end-user group is emerging medtech startups, which typically lack both manufacturing infrastructure and mature quality systems and therefore depend on CMO/CDMO partners from early development through commercial scale.

Finally, reshoring and nearshoring are accelerating as organizations respond to geopolitical risk, tariff exposure of 10% to 25% on medical devices and components under the U.S.-China tariff regime, and supply chain fragility exposed by recent disruptions. Critically, this trend carries compliance implications, not merely logistical ones, a point that becomes clearer under the new QMSR inspection approach.

Understanding the Regulatory Architecture: The Dual-Framework Problem Explained

For a standard medical device, the regulatory framework is relatively clear. Manufacturers operate under FDA device quality requirements, now consolidated under the QMSR and 21 CFR Part 820, alongside ISO 13485:2016. One framework, one primary lens.

Combination products shatter that simplicity. When a product combines a drug and a device, or a biologic and a device, 21 CFR Part 4 requires compliance with both pharmaceutical cGMP and device quality management system requirements simultaneously. These are not alternative pathways to choose between; they apply at the same time, to the same product.

Central to this is the Primary Mode of Action (PMOA) determination. The PMOA dictates which FDA center leads the review: the Center for Drug Evaluation and Research (CDER), the Center for Devices and Radiological Health (CDRH), or the Center for Biologics Evaluation and Research (CBER). This is a critical early-stage decision that shapes the entire regulatory and manufacturing strategy. Selecting a manufacturing partner before understanding the PMOA is putting the cart before the horse.

For biologic-device combinations, a third regulatory layer applies. Under 21 CFR Part 4, if a combination product includes a biological product constituent, the manufacturer must comply with all manufacturing requirements that would apply to that biological product as if it were not part of a combination. Human cells, tissues, and cellular and tissue-based products (HCT/Ps) carry their own obligations that do not disappear simply because they are embedded in a device.

For products targeting European markets, the EMA ATMP GMP framework adds yet another dimension. The EMA’s July 2025 guideline on clinical-stage ATMPs directly influences which manufacturing partners are viable for companies pursuing EU approval.

Selecting a CMO or CDMO without understanding this multi-layered architecture is one of the most common and costly mistakes made by early-stage companies entering the combination product or ATMP space.

The February 2026 QMSR Transition: What It Really Means for Combination Product Manufacturers

Effective February 2, 2026, the FDA amended 21 CFR Part 820 to incorporate ISO 13485:2016 by reference, replacing the legacy Quality System Regulation and harmonizing U.S. device quality requirements with the standards used by other regulatory authorities (FDA). For many device manufacturers, this represents a genuine simplification.

The strategic implication most commentary misses, however, is this: the QMSR transition updated Part 4 references, yet it did not change the underlying cGMP obligations for combination products. As SGS notes, nothing has changed regarding the requirements for medical device combination products; those products still carry their own regulations. The full pharmaceutical and biological manufacturing requirements remain intact.

The inspection landscape also shifted. The old FDA Quality System Inspection Technique (QSIT) was retired on February 2, 2026, replaced by the updated Inspection of Medical Device Manufacturers Compliance Program (CP 7382.850). This changes how the FDA inspects contract manufacturers and their quality systems.

Crucially, the new inspection approach places greater emphasis on supplier controls and outsourced process management. A CMO’s quality system maturity therefore becomes a direct compliance variable for the original equipment manufacturer (OEM), not merely a vendor preference. When the FDA inspects, weaknesses in a manufacturing partner’s systems become the OEM’s regulatory exposure.

Combination product manufacturers should also anticipate further QMSR refinements throughout 2026, particularly around risk documentation, data integrity, and supplier qualification, as the FDA rolls out new inspection tools and training (Hogan Lovells).

The practical takeaway is direct: buyers must verify that a partner has already transitioned to full QMSR compliance, not merely holds ISO 13485 certification, and that the partner’s quality system explicitly addresses combination product obligations under 21 CFR Part 4.

ATMP and Regenerative Medicine: A Manufacturing Category of Its Own

Advanced therapy medicinal products, including cell therapies, gene therapies, and tissue-engineered products, occupy a manufacturing category unlike any other. When these therapies also incorporate device components, the multi-framework compliance obligations multiply.

Several characteristics distinguish ATMPs from conventional biologics or devices. Scale-up is exceptionally complex. Cold chain logistics for living cell products are unforgiving. Product shelf life can be extraordinarily short, sometimes measured in hours. Patient-specific (autologous) production also requires an entirely different operational model from batch manufacturing.

Perhaps the most defining requirement is GMP for a single patient. Even when an ATMP is produced for one individual, it must be manufactured and controlled under full GMP-compliant practices, with standardized and validated processes performed by qualified personnel under rigorous conditions, with each step carefully documented. This is non-negotiable, and it eliminates the vast majority of generalist CMOs from consideration.

The distinction between autologous and allogeneic production models drives significant manufacturing consequences. Autologous therapies, derived from a single patient’s own cells, demand individualized batch management and rigorous chain-of-identity controls. Allogeneic therapies, produced from donor material for multiple recipients, permit more conventional scale-up but introduce their own comparability challenges across batches.

The market reflects both opportunity and structural imbalance. The cell and gene therapy CDMO market is projected to grow from USD 8.07 billion in 2025 to USD 74.03 billion by 2034 at a CAGR of 27.92%, yet it faces overcapacity in adeno-associated virus (AAV) vector manufacturing alongside high per-patient costs for autologous cell therapies (PubMed Central).

Point-of-care manufacturing is emerging as a compelling model, and both the FDA and EMA are adapting their frameworks to accommodate decentralized manufacturing, including FDA draft guidance on CAR-T multisite manufacturing.

Key Criteria for Evaluating a CMO/CDMO for Combination and Biologic Products

Selecting a partner for advanced products requires a multi-dimensional vetting framework, not a single checklist. The criteria below are organized around four pillars: regulatory capability, technical capability, quality system maturity, and strategic fit.

Regulatory Capability and Dual-Framework Experience

• Confirm documented dual-framework experience. Verify that the partner has operated under both device quality management systems (QMSR/ISO 13485:2016) and pharmaceutical cGMP simultaneously, not just one or the other.
• Assess 21 CFR Part 4 and PMOA fluency. Confirm that the partner can actively support regulatory strategy, including the PMOA determination process, rather than simply executing manufacturing instructions.
• Verify EU readiness where applicable. For products targeting European markets, confirm EMA ATMP GMP compliance and familiarity with EUDAMED requirements, which entered operational phase in 2026 and require unified master data, UDI traceability, and electronic vigilance records.
• Review inspection history under CP 7382.850. A clean FDA inspection record under the updated compliance program is a meaningful signal of quality system maturity.
• Ask about early regulatory touchpoints. Experience with Pre-RFD (Request for Designation) submissions in the U.S. and early Notified Body engagement in the EU adds significant strategic value.

Technical and Biological Manufacturing Capabilities

• For biologic-device combinations, assess GMP-grade cell banking capabilities, viral vector containment infrastructure, aseptic process simulation protocols, and biocompatibility testing for implantable components.
• For ATMPs, evaluate cold chain management systems, chain-of-identity controls for autologous products, and demonstrated experience with short-shelf-life logistics.
• Scrutinize technology transfer capability. A failed or incomplete technology transfer is one of the leading causes of program delays and regulatory failures. Request documented case studies and success metrics.
• Evaluate digital infrastructure. Leading CDMOs in 2026 use AI and machine learning to automate computer-aided design, reducing R&D cycles by up to 30%, and deploy digital twins to simulate production lines virtually before physical manufacturing begins.
• Confirm full-scope capability. The partner’s services should extend beyond assembly to include design transfer, component fabrication, sterilization coordination, packaging, validation, regulatory support, and post-market surveillance support.

Quality System Maturity and QMSR Alignment

• Verify QMSR compliance, not just ISO 13485 certification. Confirm the partner has formally transitioned and that its quality system explicitly addresses the CP 7382.850 inspection framework.
• Assess supplier qualification protocols. Under QMSR, the FDA holds OEMs accountable for their CMO’s quality system performance, making this a direct regulatory risk.
• Review risk documentation and data integrity practices. These are the areas where the FDA has signaled the most scrutiny under the new inspection tools.
• Confirm integrated dual-framework quality systems. For combination products, the quality system must integrate both device QMS and pharmaceutical cGMP requirements, with documented procedures for managing the interface between them.
• Evaluate change control and CAPA systems. In a multi-framework environment, a process change affecting the biologic constituent may trigger obligations affecting the device design history file, and vice versa.

IP Protection and Contractual Safeguards

Most CMO selection guides ignore the IP dimension entirely, yet development-stage manufacturing generates valuable new IP: cell line improvements, purification innovations, analytical methods, and process optimizations. These must be explicitly assigned in contracts.

The risk is acute for biotech startups. A CMO that retains background IP rights to manufacturing processes can create significant barriers to switching partners or achieving regulatory approval with a different manufacturer. When the manufacturing process is the product, ceding IP control can undermine the entire enterprise.

Key contractual provisions to evaluate include IP ownership and assignment clauses, confidentiality and data protection terms, exclusivity provisions and their limits, and rights to reference regulatory filings. Buyers should also assess data segregation: in a multi-client CMO environment, robust segregation protocols protect confidential process data and regulatory submissions from inadvertent disclosure.

Engaging legal counsel with combination product or biologics manufacturing experience before finalizing any agreement is strongly recommended. The contractual complexity of these partnerships exceeds that of standard device manufacturing agreements.

Strategic Fit and Partnership Structure

• Engage early, at the process development stage. Early engagement allows the partner to design manufacturing processes with regulatory approvability built in from the outset.
• Evaluate manufacturing incubation offerings. For startups, accessing GMP-compatible process development, analytical method development, and small-scale GMP manufacturing under one roof conserves capital while advancing toward milestones.
• Assess geographic alignment. North America dominates the market with approximately 35% to 40% share in 2025-2026, and domestic or nearshore manufacturing now carries a compliance advantage under QMSR’s supplier control requirements, not just a logistics benefit.
• Plan for scalability. The partner should support the product from clinical-stage manufacturing through process validation to commercial scale, or have a documented technology transfer pathway.
• Examine governance structures. Complex, multi-framework products require dedicated regulatory liaisons, joint quality agreements, and defined escalation protocols, not a standard service agreement.

Common Pitfalls to Avoid When Selecting a CMO/CDMO for Advanced Products

• Pitfall 1: Treating selection as a single-checklist exercise. Evaluating a partner against only one framework, such as ISO 13485, when the product requires dual or triple compliance is the most common and consequential error.
• Pitfall 2: Delaying regulatory strategy until after selection. The PMOA determination and early FDA/EMA engagement should inform partner selection, not follow it. A partner chosen before the pathway is defined may lack the specific capabilities required.
• Pitfall 3: Underestimating technology transfer risk. Assuming a well-documented process will transfer seamlessly is a frequent cause of delay. Transfer milestones and success criteria should be built directly into the contract.
• Pitfall 4: Neglecting IP ownership terms. Accepting a CMO’s standard contract without negotiating IP assignment can create lasting strategic liabilities, especially for startups whose value resides in their process.
• Pitfall 5: Selecting on cost alone. The industry has moved decisively toward resilience-led supply chain strategies. A partner chosen on cost that lacks dual-framework capability generates far greater downstream costs through regulatory failures and delays.
• Pitfall 6: Overlooking EU digital compliance. Partners without operational EUDAMED integration and UDI traceability create a compliance gap that cannot be remediated quickly for products targeting European markets.

The Startup Perspective: Structuring the CMO Relationship from Day One

Emerging medtech and biotech startups are the fastest-growing end-user segment in contract manufacturing, and they face the highest risk from poorly structured relationships. Startups often lack the manufacturing infrastructure and quality systems required for commercial production. A capable partner can provide prototyping, design-for-manufacturing support, process validation, pilot production, and scalable manufacturing, allowing them to conserve capital while progressing toward milestones.

The strategic recommendation for founders is to treat the CMO or CDMO as a co-development partner from the earliest feasible stage. This is especially true for ATMP and combination products, where the manufacturing process is, in a regulatory sense, the product itself.

Startups also typically lack the internal quality management infrastructure required for commercial production. A partner able to operate within a shared quality framework, while the startup builds its own systems in parallel, provides a critical bridge across a vulnerable period.

There is an investor dimension as well. Sophisticated investors in the ATMP and combination product space increasingly scrutinize the CMO/CDMO relationship as a risk factor. A well-structured partnership with a credentialed manufacturer strengthens the investment case, while a fragile or poorly documented one raises red flags during due diligence. Teams seeking to understand how regenerative medicine clinical studies intersect with manufacturing strategy will find that the two disciplines are inseparable at this stage.

The practical recommendation is unambiguous: engage regulatory counsel and a CMO/CDMO with combination product or ATMP experience simultaneously, before finalizing the product development plan, not after.

Conclusion: CMO Selection as Strategic Architecture

For biologic-device combination products, ATMPs, and regenerative medicine constructs, selecting a contract manufacturing partner is not an operational procurement decision. It is a foundational strategic architecture choice that shapes regulatory outcomes, IP position, time to market, and long-term scalability.

The dual-framework problem sits at the heart of it. The convergence of device quality systems under the QMSR, pharmaceutical cGMP under 21 CFR Part 4, and ATMP GMP frameworks creates a compliance environment that only a subset of CMOs and CDMOs are genuinely equipped to navigate. The February 2026 QMSR transition, while harmonizing certain requirements, has raised the bar for supplier qualification and quality system maturity rather than lowered it.

The market context reinforces the urgency. With the ATMP CDMO market projected to reach USD 54.89 billion by 2035 and the broader medical device contract manufacturing market on track for USD 140.84 billion by 2030, competition for qualified partners is intensifying. Early engagement with the right partner is not merely prudent; it is a strategic advantage.

Organizations developing advanced combination products or ATMPs benefit most from a manufacturing partner who understands the full regulatory architecture, brings proven dual-framework experience, and can serve as a true strategic extension of the development team from process development through commercial scale.

Ready to Navigate the Dual-Framework Challenge?

For teams developing biologic-device combination products, ATMPs, or regenerative medicine constructs, the right manufacturing partner is one who understands the full regulatory and technical complexity of the product category, not a generalist retrofitting a standard device workflow.

A productive next step is a consultation focused on the specifics: the product’s likely PMOA and regulatory pathway, its combination or biologic manufacturing requirements, and how a specialized CMO/CDMO can support development and commercialization goals. This is a conversation grounded in the realities described throughout this guide, including QMSR compliance, 21 CFR Part 4 obligations, ATMP GMP expectations, and the convergence-zone challenges that define advanced product manufacturing.

Teams working in this space are invited to connect with adiamed to open that strategic dialogue on their own timeline. The goal is not a transaction, but a partnership architected for the compliance environment these products actually inhabit.